Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis.

Autor: Skoie IM; Department of Dermatology, Stavanger University Hospital, Stavanger, Norway., Dalen I; Section of Biostatistics, Research Department, Stavanger University Hospital, Stavanger, Norway., Omdal R; Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway. roald.omdal@lyse.net.; Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway. roald.omdal@lyse.net.
Jazyk: angličtina
Zdroj: American journal of clinical dermatology [Am J Clin Dermatol] 2019 Aug; Vol. 20 (4), pp. 493-502.
DOI: 10.1007/s40257-019-00434-w
Abstrakt: Background: Fatigue is frequent in patients with psoriasis. Though conventional drugs in general have no effect on fatigue, biological agents have demonstrated beneficial effects in several other chronic inflammatory diseases.
Objective: The objective of the present study was to evaluate the effect of biological drugs on fatigue in patients with psoriasis vulgaris.
Methods: We conducted a meta-analysis of randomized controlled trials in which anti-interleukin-12/23, anti-interleukin-23, anti-interleukin-17, or anti-tumor necrosis factor-α agents were used for psoriasis vulgaris and fatigue was an outcome measure.
Results: A total of eight randomized controlled trials fulfilled criteria for inclusion in the meta-analysis. The studies used two fatigue reporting scales: the Functional Assessment of Chronic Illness Therapy-Fatigue and the Short Form 36 Health Survey Vitality Subscale. Treatment by biological agents in general compared with placebo led to a significant reduction in fatigue, with a standardized mean difference of - 0.40 (95% confidence interval - 0.46 to - 0.34; p < 0.001).
Conclusion: Biological drugs used for the treatment of psoriasis vulgaris have a consistently small-to-moderate beneficial effect on fatigue independent of the type of drug.
Databáze: MEDLINE
Externí odkaz: